Научная электронная библиотека
Монографии, изданные в издательстве Российской Академии Естествознания

ПЯТЬ ШАГОВ К УСПЕШНОЙ КОНТРАЦЕПЦИИ

Дикке Г. Б.,

ЛИТЕРАТУРА

  1. Аванесян А.Р., Бегларян Г.А. Сравнительная оценка эффективности медикаментозного и хирургического аборта в ранние сроки беременности и оценка восстановления менструальной функции в послеабортном периоде. Вопросы теоретической и клинической медицины. 2011; 2: 9-14.
  2. Авдеев А.А., Троицкая И.А. Сравнительный анализ контрацептивного поведения в России, Франции, Литве и Грузии. В сб.: Инновационное развитие экономики России: ресурсное обеспечение: Вторая международная конференция; Москва, МГУ им. М.В.Ломоносова, экономический факультет; 22-24 апреля 2009 г., Сборник статей: Том 3. Под ред. В.П. Колесова и Л.А. Тутова. - М.: Экономический факультет МГУ, ТЕИС, 2009. с. 592-601.
  3. Аганезова Н.В., Линде В.А. Клинический опыт применения комбинированного монофазного орального контрацептива с дроспиреноном при синдроме предменструального напряжении./ Пробл. репрод. 2008;1:66–72.
  4. Айламазян Э.К., Тарасова М.А., Григорьева В.А, Коротеев А.Л., Чен М. Левоноргестрел-выделяющая внутриматочная система как метод лечения гиперполименореи у женщин с миомой матки. Гинекология. 2004;5:245-248.
  5. Алейникова А.Л. Оценка метаболизма стероидных гормонов и эффективности антиандрогенных препаратов в лечении андрогенной алопеции у женщин репродуктивного возраста. Автореф. … кан. мед. наук: 14.00.11 –
    кожные и венерические болезни. М., 2005. 24 с.
  6. Алесина И.Л. Консультирование женщин как важный инструмент при индивидуальном подборе метода контрацепции. Акуш. и гинек. 2011;6:120-124.
  7. Андреева В.О., Шабанова Л.Ю., Московкина А.В. и др. Сравнительная оценка эффективности применения метформина и комбинированных оральных контрацептивов в лечении девушек-подростков с ожирением и олигоменореей. Материалы Х юбилейного Всерос. науч. форума «Мать и дитя». М., 2009. С. 250-251.
  8. Артымук Н.В. Медикаментозный аборт в России (на примере опыта внедрения в Кемеровской области). Доклад на XIV Всероссийском научном форуме «Мать и дитя». Москва, 25 сентября 2013 года, г. Москва.
  9. Артымук Н.В., Букреева Е.Л. Сравнительная оценка влияния сочетания 3 мг дроспиренона и 20 или 30 мкг этинилэстрадиола на состояние кожи и антропометрические показатели. Фарматека. 2015;3:31-33.
  10. Балашова Т.Н., Дикке Г.Б., Исурина Г.Л., Шапкайц В.А., Варавикова Е.А., Цветкова Л.А., Ерофеева Л.В. Профилактика фетального алкогольного синдрома в практике акушера-гинеколога: методическое руководство // под редакцией проф. Н.М. Подзолковой. Москва: ГБОУ ДПО РМАПО, 2012. 90 с.
  11. Басова О.Н., Волков В.Г. Сравнительная характеристика эффективности комбинированных оральных контрацептивов в терапии ПМС: рандомизированное контролируемое исследование. Проблемы репродукции. 2011;4:27-31.
  12. Басова О.Н., Волков В.Г. Опыт применения комбинированного орального контрацептива, содержащего дроспиренон. Материалы Х юбилейного Всерос. науч. форума «Мать и дитя». -М., 2009. С. 259-260.
  13. Борисов В.А. Демография и социальная психология. М., 1970.
  14. Бебнева Т.Н. Сексуальное насилие и вопросы контрацепции. Гинекология. 2002;4(6):29-30.
  15. Бебнева Т.Н., Дикке Г.Б. Отвечая потребностям подростков. В тренде – пролонгированная контрацепция, в фокусе – качество консультирования. Фарматека. 2014;12(285):22-27.
  16. Бирюкова С., Тындик А. Регистрация брака и рождение ребенка в биографии россиян: анализ данных текущей статистики. Демографическое обозрение. 2014;1(3):33-64.
  17. Бурдули Г. М., Фролова О. Г. Репродуктивные потери. М.: Триада-Х, 2008.
  18. Василенко Л.Н., Новикова Е.И. Тактика ведения пациенток с миомой матки в сочетании с генитальным эндометриозом после органосохраняющих операций. РМЖ – Акуш. и гинек. 2014;1:54-59.
  19. ВОЗ. Экстренная контрацепция. Информационный бюллетень № 244. Июль 2012. – Электронный ресурс. – Режим доступа: http://www.who.
  20. Геворкян М.А., Манухин И.Б., Тихомиров А.Л., Кузнецова Е.М. Опыт применения дроспиренон-содержащего гормонального контрацептива. РМЖ. 2011;1:22.
  21. Григорьева В.А., Айламазян Э.К., Тарасова М.А., Коротеев А.Л., Чен М. Левоноргестрелвыделяющая внутриматочная система как метод лечения гиперполименореи у женщин с миомой матки. Гинекология 2004;6:245-248.
  22. Горшков М. Российское общество как оно есть: (опыт социологической диагностики). М.: Новый хронограф, 2011. – 672 с.
  23. Денисенко М. Российский студент в интимной жизни. Население и общество. Электронная версия бюллетеня. 2006. – Электронный ресурс. –
    Режим доступа: http://polit.ru/
  24. Денисов Б.П., Сакевич В.И. Применение контрацепции в России (по материалам выборочного обследования). Доказательная медицина и клиническая эпидемиология. 2009;1: 34-39.
  25. Денисов Б.П., Сакевич В.И. Аборты в постсоветской России: есть ли основания для оптимизма? Демографическое обозрение (электронный научный журнал. 2014, №1, с. 144–169. – Электронный ресурс. – Режим доступа: http://demreview.hse.ru/about
  26. Дикке Г.Б., Яроцкая Е.Л., Ерофеева Л.В. Стратегическая оценка политики, программ и услуг в сфере непланируемой беременности, абортов и контрацепции в Российской Федерации. Совместное исследование МЗ и СР РФ и ВОЗ. Проблемы репродукции. 2011;3:92-108.
  27. Дикке Г.Б., Тараленко С.В., Яговкина И.А. и др., Оптимизация процесса построения диагноза при лейомиоме матки и выбор критериев оценки динамики течения заболевания. Фундаментальные иссл. 2010;10:111-116.
  28. Дикке Г.Б., Кутуева Ф.Р. Опыт прерывания беременности одной таблеткой мифепристона (200 мг) в комбинации с мизопростолом в амбулаторной практике женской консультации № 22 г. Санкт-Петербурга. Земский врач. 2012;4(15):25-31.
  29. Дикке Г.Б., Ерофеева Л.В. Особенности репродуктивного поведения молодежи. Акуш. и гинек. 2013;12:96-101.
  30. Дикке Г.Б., Ерофеева Л.В., Яроцкая Е.Л.. Аборты и контрацепция в России на фоне демографического кризиса. Эфф. фармакотерапия. 2013;51:48-55.
  31. Дикке Г.Б. Профилактика повторной нежелательной беременности. Выбор метода контрацепции. Акуш. и гинек. 2014;4:81-87.
  32. Дикке Г.Б. Факторы и методы, определяющие приверженность к гормональной контрацепции. РМЖ. Акуш. и гинек. 2014;1:1-4.
  33. Дикке Г.Б. Контрацепция среди жительниц Москвы, страдающих гинекологическими заболеваниями. Фарматека. 2014;12(285):16-21.
  34. Дикке Г.Б., Ерофеева Л.В. Современные особенности национальной контрацепции: информированность, применение и эффективность. Вопросы гинек., акуш. и перинат. 2014;1(5):63–71.
  35. Дикке Г.Б. Контраверсии безопасного и небезопасного аборта. Доктор.ру. Гинекология. Эндокринология. 2014; 8(96),I: 51-55.
  36. Дикке Г.Б. Медикаментозный аборт: Руководство для врачей / Под ред. В.Е. Радзинского. – М.: МЕДпресс-информ, 2015. – 344 с.: ил.
  37. Доброхотова Ю.Э., Шингарёва Т.А. Новые возможности применения орального дезогестрела 75 мкг у больных эндометриозом. Русский медицинский журнал. 2009;16:1024–1027.
  38. Доклад о человеческом развитии в РФ за 2008 г.: Россия перед лицом демографических вызовов / Под общей редакцией А.Г. Вишневского и С.Н. Бобылева. М.: ЗАО «ПриПресс Интернэшнл»; «Сити-Принт», 2009:208 с.
  39. Дремова Н.Б., Холодова Е.В. Современный рынок контрацептивных средств: маркетинговый анализ. Маркетинг в России и за рубежом. 2004; 6. – Электронный ресурс. – Режим доступа: http://dis.ru/library/529/25250/.
  40. Жук С.И., Захурдаева Л.Д. Особенности современного консультирования по вопросам контрацепции. Медицинские аспекты здоровья женщины. 2011;4(43). —Электронный ресурс. – Режим доступа: http://www.fetalmedic.com/.
  41. Жовтун Л.М. Опыт применения медикаментозного аборта у подростков в республике Бурятия. Доклад на I Научно-практической конференции с международным участием «Национальный и международный опыт охраны репродуктивного здоровья девочек». 4 июня 2013 года, г. Москва.
  42. Здравоохранение в России – 2013. Федеральная служба государственной статистики. 2011. – Электронный ресурс. – Режим доступа: http://www.gks.ru/
  43. Илюхина О.В. Современная социально-психологическая модель сохранения репродуктивного здоровья женщин фертильного возраста. Автореф. ... дисс. канд. мед. наук. Волгоград, 2012. – 24 с.
  44. Камалова Е.В. Контрацептивный выбор девушек-подростков Г. Томска в современных условиях. НАУКИ О ЧЕЛОВЕКЕ. Материалы VIII конгресса молодых ученых и специалистов. Томск, 17-18 мая 2007 года / Под редакцией Л.М. Огородовой, Л.В. Капилевича. Томск, 2007:153.
  45. Карахалис Л.Ю., Жигаленко А.Р., Стебло Е.И. Контрацептивные и неконтрацептивные эффекты дроспиренона. Репродуктивное здоровье детей и подростков. 2015;2:73-77.
  46. Кузнецова И.В., Бурчаков Д.И. Гормональная контрацепция и микронутриенты: задача, требующая решения. Consilium Medicum. 2014;6:
    33-42.
  47. Кузнецова И.В. Гормональная контрацепция у подростков и молодежи. Трудный пациент. 2010;8(8):4-9.
  48. Кузнецова И.В. Метаболические эффекты гормональных контрацептивов. Презентация. Электронный ресурс. Режим доступа: http://medi.ru/doc/262711.htm
  49. Кузнецова И.В. Контрацептивные гормоны в ранней профилактике метаболических рисков синдрома поликистозных яичников. Репродуктивное здоровье детей и подростков. 2012;3: 42-51.
  50. Ледина А.В. Дроспиренонсодержащий контрацептив: лечебные и профилактические аспекты применения. Гинекология. 2015;1:25-29.
  51. Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ», 4-е изд., 2009. М., 2012. 178 с.
  52. Межевитинова Е.А., Куземин А.А. К вопросу о лечении дисменореи и предменструального синдрома. Гинекология. 2001;3(4):133-134.
  53. Методическое письмо МЗ РФ № 15-4/10/2-1694 от 21 февр. 2011 г.
    О материнской смертности в Российской Федерации в 2009 году. М., 2010.
  54. Методическое письмо МЗ РФ №15-4/10/2-7-65 от 19.09.2013 О материнской смертности в РФ в 2012 году. М., 2013.
  55. Минкина Г.Н. Гормональные контрацептивы и риск цервикальной неоплазии. Вопросы гинек., акуш. и перинат. 2013;12 (1):56-63.
  56. Назарова Н.М. Гормональные релизинг-системы и репродуктивное здоровье женщин. Международный эндокринологический журнал. 2010;3(27). – Электронный ресурс. – Режим доступа: http://www.mif-ua.com/.
  57. Население и общество (электронная версия журнала), 2013 г. – Электронный ресурс. – Режим доступа: http://www.polit.ru.
  58. Осипова А.А., Адамян Л.В., Нестеровская И.В. Эффективность и безопасность гормональной вагинальной системы НоваРинг у женщин репродуктивного возраста. Современные технологии в диагностике и лечении гинекологических заболеваний. - М.: Пантори, 2008. – 37 с.
  59. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации // Сборник статистических материалов. М., 2013. – 200 с.
  60.  Острейкова Л.И., Прилепская В.Н. Терапевтические аспекты левоноргестрел-рилизинг-системы. Гинекология. 2001;3(1):4-10.
  61. Ошибки при использовании презервативов. 31.01.2013. Сайт EHPV. Электронный ресурс. Режим доступа: http://ehpv.ee/
  62. Планирование семьи. Универсальное руководство для поставщиков услуг по планированию семьи. ВОЗ, Институт Джона Хопкинса Блюмберга, Агентство США по международному развитию. Ьалтимор, Женева, 2007. 490 с.
  63. Плотко Е.Э. Прогнозирование, профилактика, диагностика и лечение осложнений искусственного прерывания беременности: Автореф. дис. …
    д-ра мед. наук. М., 2013. 48 с.
  64. Подзолкова Н.М., Ерофеева Л.В., Сафина Э.М., Сумятина. Мифы о контрацепции в современной России. Фарматека. 2014;12(285):8-12.
  65. Подзолкова Н.М. Коренная В.В. Лечебные эффекты гормональных контрацептивов (обзор литературы). Гинекология. 2012;2:57-61.
  66. Подзолкова Н.М. Гормональная контрацепция: вопросы безопасности и переносимости // Новости медицины и фармации. — 2009. — № 275.
  67. Попов А.А. Аборты в России. В кн.: БИОЭТИКА: принципы, правила, проблемы. М.: Эдиториал УPCC, 1998. – Электронный ресурс. – Режим доступа: http://www.booksite.ru/.
  68. Порядок оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)» (Приказ Министерства здравоохранения Российской Федерации от 1 ноября 2012 г. No 572н г. Москва; зарегистрирован в Минюсте РФ 2 апреля 2013 г. Регистрационный №27960). - Электронный ресурс. – Режим доступа: http://www.garant.ru/.
  69. Пособие по консультированию «ПОМОГИ». – Факультет охраны здоровья ун-та им. Дж. Хопкинса. ‒ Центр коммуникативных программ, 1998.
  70. Пресс-выпуск ВЦИОМ №1403 от 5 января 2010 г. Электронный ресурс. – Режим доступа: http://wciom.ru/.
  71. Прилепская В.Н., Назарова Н.М., Тарасова М.А., Летуновская А.Б. Международный проект «CHOICE»: краткий обзор результатов исследования. Гинекология. 2010;4:26–28.
  72. Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р. От аборта к сохранению репродуктивного здоровья: новое в контрацепции. Фарматека. 2013; 12(265):46-50.
  73. Прилепская В.В., Межевитинова Е.А., Назарова Н.М. Контрацептивные и лечебные аспекты современных методов контрацепции (клинические лекции) - М.: МЕДпресс-информ, 2006. - 128 с.
  74. Прилепская В.Н. Руководство по контрацепции. Второе изд. М., 2011. 448 с.
  75. Прилепская В.Н., Абакарова П.Р. Внутриматочная гормональная левоноргестрел-рилизинг система у женщин в перименопаузе. Фарматека. 2010;1:17-21.
  76. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А. и др. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акуш. и гин. 2012;2:81-85.
  77. Прилепская В.Н., Новикова Е.П. Дроспиренон-содержащие контрацептивные средства – возможности расширяются. Фарматека. 2012;12(245):49-52.
  78. Причины отказа от гормональной контрацепции. Женское здоровье. 2013. Электоронный ресурс. – Режим доступа: http://rybelm.ru/.
  79. Пустотина О.А. Тромбофилические риски современной гормональной контрацепции. Фарматека. 2014;12:12-15.
  80. Ранние сроки беременности (2-е изд., испр. и доп) / Под ред. В.Е. Радзинского, А.А. Оразмурадовова. М.: Status Praesens, 2009. 480 с.
  81. Репродуктивное здоровье населения России. Резюме отчета. Федеральная служба государственной статистики. Министерство здравоохранения Российской Федерации. Фонд ООН в области народонаселения (ЮНФПА). М., 2012. 58 с.
  82. Репродуктивное здоровье и фертильность в Санкт-Петербурге: Отчёт по результатам опроса, проведённого среди женщин от 18 до 44 лет в 2004 году. Department of Sociology, University of Helsinki. Working Papers, No. 60, 2005.
  83. Родители и дети, мужчины и женщины в семье и обществе. Сборник аналитических статей. Выпуск 2. Под науч. ред. С.В. Захарова, Т.М. Малевой, О.В. Синявской. М.: НИСП, 2009. 336 с. – Электронный ресурс. – Режим доступа: http://www.socpol.ru/.
  84. Садвокасова Е.А. Социально-гигиенические аспекты регулирования размеров семьи. М.: Медицина, 1969: 30.
  85. Сакевич В.И., Денисов Б.П. Перейдет ли Россия от аборта к планированию семьи? Демоскоп Weekly № 465 – 466, 2 - 22 мая 2011. – Электронный ресурс. Режим доступа: http://www.demoscope.ru.
  86. Сакевич В.И. Планирование семьи в России. Демоскоп Weekly № 465 – 466, 14 марта 2010. – Электронный ресурс. Режим доступа: http://www.demoscope.ru.
  87. Сасунова Р.А., Межевитинова Е.А. Предменструальный синдром. Гинекология. 2010;6:34–38.
  88. Сергиенко М.Ю., Ласачко С.А. Проблема подростковой мастопатии и комбинированные оральные контрацептивы // Медико-соціальні проблеми сім’ї. — 2006. — Т. 11, № 2. — С. 153-156.
  89. Серов В.Н. Гормональная контрацепция как метод реабилитации после абортов. РМЖ. Акушерство и гинекология. 2010;2:26-28.
  90. Серов В.Н., Кожин А.А. Эколого-генеративный диссонанс и патофизиологические аспекты нарушений генеративной функции центрального генеза // Акушерство и гинекология. 1988. - № 8. - С. 12-15.
  91. Соболева Е.Л. Комбинированные оральные контрацептивы, содержащие дроспиренон или ципротерона ацетат, в терапии угревой сыпи. Журн. акуш. и жен. бол. 2009;2:53-56.
  92. Стандарты сексуального образования в Европе. Документ для лиц, определяющих политику, руководителей и специалистов в области образования и здравоохранения. Европейское региональное бюро ВОЗ и ФЦПСЗ. Федеральный центр просвещения в сфере здравоохранения, ФЦПСЗ. Кёльн, 2010: 71 с.
  93. Сумятина Л.В. Метаболические эффекты микро- и низкодозированных гормональных контрацептивов у женщин с избыточной массой тела и умеренным ожирением: Дис. … канд. мед. наук. М., 2006. 118 с.
  94. Таблетки для экстренной контрацепции. Международный консорциум по экстренной контрацепции, Международная федерация гинекологии и акушерства (FIGO). Третье изд., пер. на рус. яз. 2012:16 с.
  95. Тарасова М.А. Программа CHOICE - «Здоровая Контрацепция» в России. Акуш., гинек. и репродукция. 2009;1:4-5.
  96. Тарасова М.А. Новые направления гормональной контрацепции. Доктор.Ру. Журнал современной медицины, выпуск 2005-04. – Электронный ресурс. Режим доступа: www.medafarm.ru
  97. Тихомиров А.Л., Лубнин Д.М. Контрацепция у больных миомой матки. РМЖ. 2002;4:213-215.
  98. Тихомиров А.Л., Леденкова А.А., Батаева А.Е.. Патогенетическое обоснование профилактики миомы матки. Вопр. гинек. акуш. и перинат. 2011;10(1):75-78.
  99. Тихомиров А.Л., Батаева А.Е. Лучше поздно, чем никогда. РМЖ. Акушерство и гинекология. 2013;1:26-30.
  100. Тихомиров А.Л. Комбинированная по составу и востребованности гормональная контрацепция. РМЖ. 2014;1:38.
  101. Томилова М.В. Прогностические факторы и патогенетические механизмы развития гиперпластических процессов эндометрия у женщин с хронической ановуляцией. Дисс. ... канд. мед. наук. 2006. 109 с.
  102. Троицкая И.А., Андерссон Г. Переход к современной контрацепции в России: Результаты обследований «Репродуктивное здоровье женщин» 1996 и 1999 гг. В кн.: Рождаемость и планирование семьи в России: История и перспективы: Сборник статей / под ред. И.А. Троицкой, А.А. Авдеева - М.: ТЕИС, 2011. - Демографические исследования, выпуск 18, с. 61-88.
  103. Тюрюканова Е.В. Женщины-мигранты из стран СНГ в России /
    Е.В. Тюрюканова (ред.), Ж.А. Зайончковская, Л.Б. Карачурина, Н.В. Мкртчян, Д.В. Полетаев, Ю.Ф. Флоринская / под ред. Е.В.Тюрюкановой. – М.: МАКС Пресс, 2011:119 с.
  104. Уварова Е.В. Комбинированная гормональная контрацепция у сексуально активных подростков и молодежи. РМЖ. 2008;19:1232.
  105. Федеральная служба гос. статистики. Демография. Численность и состав населения. Электронный ресурс. – Режим доступа: http://www.gks.ru/
  106. Федеральная служба гос. статистики. О соотношении денежных доходов населения с величиной прожиточного минимума и численности малоимущего населения в целом по Российской Федерации в I квартале 2015 года. Электронный ресурс. – Режим доступа: http://www.gks.ru/
  107. Федеральный закон от 21 ноября 2011 г. №323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации» (Собрание законодательства Российской Федерации, 2011, № 48, ст. 6724; 2012, №26, ст. 3442, 3446). - Электронный ресурс. – Режим доступа: http://www.rg.ru/.
  108. Хамошина М.Б., Лебедева М.Г., Вострикова Т.В., Архипова М.П., Руднева О.Д. Контрацептивное поведение студенток вуза: возможности и перспективы коррекции. Репродуктивное здоровье детей и подростков, 2010.-N 5.-С.75-88.
  109. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2004. 168 с.
  110. Чепик О.Ф. Морфогенез гиперпластических процессов эндометрия //
    Практическая онкология. 2004;5(1):9–15.
  111. Эндометриоз: диагностика, лечение и реабилитация. Клинические рекомендации (протокол лечения). Утверждены МЗ РФ от 22 ноября 2013 г.
    N 15-4/10/2-8710.
  112. Abdel-Aleem H., D’Arcangues C., Vogelsong K.M. et al. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. The Cochrane database of systematic reviews, 2013, 10, pp. CD003449.
  113. American College of Obstetricians and Gynecologists. Practice Bulletin №. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115:206.
  114. Ahrendt HJ, Makalova D, Parke S et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–44.
  115. Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451–7.
  116. Agren U.M., Anttila M., Maenpaa-Liukko K. et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism./Eur J Contracept Reprod Health Care. 2011;16: 444-457.
  117. American Psychological Association, Task Force on Mental Health and Abortion. (2008). Report of the Task Force on Mental Health and Abortion. Washington, DC: Author. Retrieved from http://www.apa.org/
  118. American College of Obstetricians and Gynecologists. Long-acting reversible contraception: implants and intrauterine devices. Guideline Summary. 2011 Jul. NGC:008627. Retrieved from http://www.guideline.gov/
  119. Ancel PY, Lelong N, Papiernik E, Saurel-Cubizolles MJ et al. EUROPOP. History of induced abortion as a risk factor for preterm birth in European countries: results of the EUROPOP survey. Hum Reprod. 2004;19(3):734-40.
  120. Andersson J., Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia // Br J Obstet Gynecol. 1990;97:697.
  121. Apter D., Borsos A., Baumgдrtner W. et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Hlth Care. 2003;8(1):37-51.
  122. Arowojolu A. O., Gallo M. F., Lopez L. M., Grimes D. A. Combined oral contraceptive pills for the treatment of acne // Cochrane Database Syst. Rev. 2012. Vol. 7. CD004425.
  123. Armstrong C. Practice Guidelines. ACOG Guidelines on Noncontraceptive Uses of Hormonal Contraceptives. Am Fam Physician. 2010;82(3):288-295.
  124. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne (Review). The Cochrane Library 2012, Issue 7. Electronic resource. Access mode: http://onlinelibrary.wiley.com/.
  125. Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 2010; 95(5):2009-2724.
  126. Astedt B., Jeppsson S., Liedholm P. et al. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17beta-oestradiol.Br J Obstet Gynaecol. 1979;86:732–736.
  127. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011; 3: 25–35.
  128. Balachova T, Bonner B, Chaffin M, Bard D, Isurina G, Tsvetkova L, Volkova E. Women’s alcohol consumption and risk for alcohol-exposed pregnancies in Russia. Addiction. 2012;107(1):109-17.
  129. Barreiros F.A., Guazzelli CAF., Arau jo F.F., Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception. 2007;75:204-208.
  130. Barrington J.W., Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynecol. 1997;104: 614–616.
  131. Basdevant A., Palissier C., Degrelle H. et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception. 1991;44:599–605.
  132. de Bastos M, Stegeman BH., Rosendaal FR., Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Contraceptive pills and venous thrombosis. Cochrane Fertility Regulation Group. Cochrane Database Syst Rev. 2014 Mar 3;3:CD010813. doi: 10.1002/14651858.CD010813.pub2.http://www.cochrane.org
  133. Baumgaertner S., Merkle E. Nuvaring improves cycle control in German women. Eur J Contracept Reprod Health Care. 2004; 9:86.
  134. Bellagio consensus recommendations for action to increase access to highly effective, long-acting, reversible contraception. Statement. 2012. Retrieved from www.astra.org.
  135. Beral V, Bull D, Doll R, Peto R et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007–16.
  136. Beral V, Doll R, Hermon C, Peto R, Reeves G. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.
  137. Bergholt T, Eriksen L, Berendt N, Jacobsen M, Hertz JB. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16:2418–2421.
  138. Brzezinska-Wcislo L. Assessment of efficacy of Diane-35 in androgenetic feminine alopecia. Wiad Lek, 2003. 56: 202—5. 5. Lucky A.W., Piacquadio D.J., Ditre C.M. et al. A randomized, placebocontrolled trial of 5% and 2% toal minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol, 2004, 50: 541—53.
  139. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013:5;185(2):E115-20.
  140. Bermond P. Therapy of side effects of oral contraceptive agents with vitamin B6. Acta Vitaminol Enzymol. 1982;4(1-2):45-54.
  141. Bhattacharyaa S., A. Lowitt, E. Amalraj Rajaa, A. Jane Leee et al. Reproductive outcomes following induced abortion: a national register-based cohort study in Scotland. BMJ. 2012;2:e000911.
  142. Binefa G., Rodriguez-Moranta F., Teule A., Medina-Hayas M. Colorectal cancer: from revention to personalized medicine // World J. Gastroenterol. 2014;20(22):6786–6808.
  143. Bitzer J. Contraceptive compliance - why is contraceptive failure still so frequent? Ther Umsch. 2009;66(2):137-43.
  144. Bitzer J, Simon JA. Current issues and available options in combined hormonal contraception. Contraception. 2011;84(4):342-56.
  145. Bitzer J. Oral contraceptives in adolescent women. Best Pract Res Clin Endocrinol Metab. 2013;27(1):77-89.
  146. Bitzer J, Heikinheimo O, Nelson AL. Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet Gynecol Surv. 2015 Feb;70(2):115-30.
  147. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin. Drug Invest. 2009;29(2):73-78.
  148. Blazar A. S. Differences in hormonal patterns during the first postabortion menstrual cycle after two techniques of termination of pregnancy. Fertility and sterility. 1980; 33(5): 493.
  149. Boesen HC, Rorbye C, Norgaard M, Nilas L. Sexual behavior during the first eight weeks after legal termination of pregnancy. Acta Obstet Gynecol Scand. 2004;83:1189–1192.
  150. Bongaarts J., Westoff Ch.F. The Potential Role of Contraception in Reducing Abortion // Studies in Family Planning. 2000;31(3):193-202.
  151. Bongaarts J. The fertility-inhibiting effects of the intermediate fertility variables // Studies in Family Planning. 1982;13(6/7):179-189.
  152. Bosetti C., Bravi F., Negri E., La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum. Reprod. Up-date. 2009;15(5):489–490.
  153. Brache V, Cochon L, Jesam C, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010;25(9):2256-63.
  154. Bradley SEK, Croft TN, Rutstein SO. The Impact of Contraceptive Failure on Unintended Births and Induced Abortions: Estimates and Strategies for Reduction. 2011. 58 p. Retrieved from http://www.iussp.org/.
  155. Brito MB, Rui A, Ferriani JCM. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Research 2012; 130:355–360.
  156. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol. 1981;113(3):203–14.
  157. Broome M, Fotherby K. Clinical experience with the progestogen-only pill. Contraception. 1990;42(5):489-95.
  158. Brown JS, Adera T, Masho SW. Previous abortion and the risk of low birth weight and preterm births. Journal of Community Health. 2008; 62(1):16-22.
  159. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44(1):62–72.
  160. Cao H, Yang G, Wang Y, Liu J, Smith CA, Luo H, Liu Y. Complementary therapies for acne vulgaris. Cochrane Database Syst Rev. 19 January 2015. DOI: 10.1002/14651858.CD009436.pub2
  161. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet. 1997;59:237–43.
  162. Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36(5):358-63.
  163. Casey P. Invited commentaries on Abortion and mental health disorders. The British Journal of Psychiatry. 2008;193 (6):452-454.
  164. Charles VE, Polis CB, Sridhara SK, Blum RW. Abortion and long-term mental health outcomes: a systematic review of the evidence. Contraception. 2008;78(6):436–50.
  165. Charlton B.M., Rich-Edwards J.W., Colditz G.A. et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study. BMJ; 2014;349:6356.
  166. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483–9.
  167. Cheng L, Gulmezoglu AM, Piaggo OGGP, Ezcurra EE, Van Look PPFA. Interventions for emergency contraception (Review). Reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 1. Art. No.: CD001324; DOI: 10.1002/14651858.CD001324. pub3. Retrieved from http://www.cochrane.org/.
  168. Cheng L, Che Y, Gulmezoglu A. Interventions for emergency contraception. Cochrane Database of Systematic Reviews 2012, Issue 12. Retrieved from http://www.cochrane.org/.
  169. Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999; 106(8): 857–60.
  170. Cianci A, De Leo V. Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives. Minerva Ginecol. 2007;59(4):415-25.
  171. Cicinelli E, Einer–Jensen N, Galantino P et al. Model of counter–current transfer from vaginato urethra in postmenopausal women. Hum. Reprod. 2001;16(12):2496–2500.
  172. Coleman M, McCowan L, Farquhar C. The levonorgestrel-releasing intrauterine device: a wider role than contraception. Obstet Gynaecol. 1997; 37(2): 195-201.
  173. Committee for Medical Products for Human Use (CHMP). Guideline on clinical investigation of steroid contraceptives in women. 2005.
  174. Cornelis J.A. Hogewoning, Maaike C.G. Bleeker, et al. Condom use Promotes the Regression of Cervical Intraepithelial Neoplasia and Clearance of HPV: Randomized Clinical Trial. International Journal of Cancer. 2003;107: 811–816.
  175. Consensus Statement: Instructions for Use – Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMP. Expert Meeting on Misoprostol sponsored by Reproductive Health Technologies Project and Gynuity Health Projects July 28, 2003. Washington, DC. Retrieved from http://www.rhtp.org/.
  176. Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol. 1996;88:4–12.
  177. Crosby RA, Yarber WL, Sanders S A, Graham CA. Condom discomfort and associated problems with their use among university students. Amer J of College Health. 2000;54:143-148.
  178. Crosignani P, Vercellini P, Mosconi P et al. Levonorgestrel-releasing intrauterine device versus hysterosco endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet. Gynecol. 1997;90:257–263.
  179. Croxatto HB, Devoto L, Durand M, et al. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. Contraception. 2001;63(3):111-21.
  180. Curtis KM, Hillis SD, Marchbanks PA et al. Disruption of the endometrial-myometrial border during pregnancy as a risk factor for adenomyosis. Am J Obstet Gynecol. 2002 Sep;187(3):543-4.
  181. Davar R, Firouzabadi RD, Ara KC. Dilatation and Curettage Effect on the Endometrial Thickness. Iran Red Crescent Med J. 2013 Apr; 15(4): 350–355.
  182. David HP, Skilogianis J (eds.). From abortion to contraception: a resource to public policies and reproductive behavior in Central and Eastern Europe from 1917 to the present. Westport, CT, Greenwood Press, 1999, р. 145-164.
  183. De Bastos M, Stegeman BH., Rosendaal FR., Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Contraceptive pills and venous thrombosis. Cochrane Fertility Regulation Group. Cochrane Database Syst Rev. 2014 Mar 3;3:CD010813. doi: 10.1002/14651858.CD010813.pub2.http://www.cochrane.org
  184. De Santis M, Cavaliere AF, Straface G, Carducci B, Caruso A. Failure of the emergency contraceptive levonorgestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study. Fertil Steril 2005;84(2):296-9.
  185. Del Pup L. If the aim is ovarian cancer prevention and estrogen mediated benefits, not only endometriosis suppression, are contraceptives with ethinilestradiol better than progestogens alone? WCRJ 2014; 1 (3): e273. http://www.wcrj.net/
  186. Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002; 100: 585–593.
  187. Dickerson V. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. J Reprod Med. 2002;47(11):985-93.
  188. Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J FamPlannReprod Health Care 2010;36:123-129.
  189. Dingle K, Alati R, Clavarino A, Najman JMet al.Pregnancy loss and psychiatric disorders in young women: an Australian birth cohort study. The British Journal of Psychiatry. 2008; 193 (6): 455-460.
  190. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomized trials. Clin. Pharmacokinetics. 2005;44:429–438.
  191. Dragoman M, Petrie K, Torgal A et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception. 2013;87(4):432-6.
  192. Drossaers-Bakker KW, Zwinderman AH, van Zeben D, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002;61(5):405–8.
  193. Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care. 2010;15(5):314-25.
  194. Edelman DA, Goldsmith A, Shelton JD. Postpartum contraception. Int J Gynaecol Obstet. 1981;19(4):305-11.
  195. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004695.
  196. Egarter C, Tirri BF, Bitzer J, Kaminskyy V. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Women’s Health. 2013; 13:9.
  197. Emergency contraception. Practice Bulletin №112. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2010;115:1100–9.
  198. Emergency Contraceptive Pills: Medical and Service Delivery Guidelines, Third Edition. ECEC, 2012: 16 р.
  199. Emergency Contraception: A guideline for service provision in Europe. ECEC, 2013: 14 р.
  200. Endrikat J, Parke S, Trummer D et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78(3):218–25.
  201. Erfani A. Levels, trends, and determinants of unintended pregnancy in iran: the role of contraceptive failures. Stud Fam Plann. 2013;44(3):
    299-317.
  202. European Medicines Agency. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Product information updated to help women make informed decisions about their choice of contraception. 2014. EMA/35464/2014. 4 р.
  203. Faculty of Sexual and Reproductive Healthcare - Professional Association. Contraceptive choices for young people. Guideline Summary. 2010. Retrieved from http://www.guideline.gov/.
  204. Faculty of Sexual and Reproductive Healthcare - Professional Association. Progestogen-only implants. Guideline Summary. 2008. NGC:006465. Retrieved from http://www.guideline.gov/
  205. Faculty of Sexual and Reproductive Healthcare - Professional Association. Clinical Guidance. Quick Starting Contraception. Clinical Effectiveness Unit. September 2010. 19 р.
  206. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: Clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275–84.
  207. Falsetti L, Dordoni D, Gastaldi C, Gastaldi A. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome. Acta Eur Fertil. 1986 Jan-Feb;17(1):19-25.
  208. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1990 Dec;42(6):611-9.
  209. Family planning: a global handbook for providers: evidence-based guidance developed through worldwide collaboration. (Rev. and Updated ed. ed.). Geneva, Switzerland: WHO and Center for Communication Programs. 2011:260–300.
  210. Fanchin R, De Ziegler D, Bergeron C et al. Transvaginal administration of progesterone. Obstet.Gynecol. 1997;90(3):396–401.
  211. Farhi J, Bar-Hava I, Homburg R, Dicker D et al. Induced regeneration of endometrium following curettage for abortion: a comparative study. Hum Reprod. 1993;8(7):1143-4.
  212. Faubion SS, Maclaughlin KL, Pruthi S, Casey PM. Contraception and Hormonal Management in the Perimenopause. J Womens Health (Larchmt). 2014;28. [Epub ahead of print].
  213. Faundes A., Alvares F., Brache V., Tejada A.S. The role of the levonorgestrel IUD in the prevention and treatment of iron defcienct anemia during fertility regulation. Int J Gynecol Obstet. 1988;26:429–433.
  214. FDA. Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease end points. 2011. www.fda.gov/ .
  215. Fergusson DM, Boden JM.Abortion and mental health disorders: evidence from a 30-year longitudinal study. The British Jour of Psychiatry. 2008;193 (6):444-451.
  216. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90–96.
  217. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and anoral contraceptiveon APC resistance and SHBG: a cross-overstudy. Thromb Res. 2009;123:429–35.
  218. Foidart J.M., Wuttke W., Bouw G.M. et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestre/. Eur. J. Contracept. Reprod. Hlth Care. 2000;5:2:124-134.
  219. Franks S, Layton A, Glasier A et al. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum. Reprod. 2008;23(2):231-232.
  220. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258-69.
  221. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10(6):561-9.
  222. Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2010;81(1):8-15.
  223. Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400-8.
  224. Fu Y, Mi W, Li L et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 2014;49(7):506-9.
  225. Fugere P, Percival-Smith RK, Lussier-Cacan S et al. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception. 1990 Aug;42(2):225-34.
  226. Gainer E., Kenfack B, Mboudou E et al. Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception. 2006;74(2):118–124.
  227. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2008;(1):CD003987.
  228. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Published Online: 29 JAN 2014. Electronic resource. Access mode: http://onlinelibrary.wiley.com/
  229. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Published Online: 29 JAN 2014. Electronic resource. Access mode: http://onlinelibrary.wiley.com/
  230. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception (Review). The Cochrane Library 2013, Issue 8. Electronic resource. Access mode: http://onlinelibrary.wiley.com/
  231. Garcia L, Isaacson K. Adenomyosis: review of the literature. J Minim Invasive Gynecol. 2011;18:428–437.
  232. Gaussem P, Alhenc-Gelas M et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. Thromb. Haemost. 2011;105(3):560-7.
  233. Gemzell-Danielsson K. Mechanism of action of emergency contraception. Contraception. 2010;82(5):404–9.
  234. Gemzell-Danielsson‌ K, Sharon TC. Ulipristal acetate (ellaOne®) for emergency contraception: review of the clinical evidence. Future Science. 2011;3:467–472.
  235. Genc M, Genc B, Cengiz H. Adenomyosis and accompanying gynecological pathologies. Arch Gynecol Obstet. 2015 Apr;291(4):877-81.
  236. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am J Epidem.1991; 133:32-37.
  237. Glasier AF, Cameron ST, Fine PM, Logan SJ et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555-62.
  238. Goldenberg G. Optimizing Treatment Approaches in Seborrheic Dermatitis. J Clin Aesthet Dermatol. 2013 Feb; 6(2): 44–49.
  239. Goldstuck ND, Steyn PS. Intrauterine contraception after cesarean section and during lactation: a systematic review. International Journal of Women’s Health. 2013;5:811-818.
  240. Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion. Contraception. 2008;78:143–8.
  241. Grady WR, Tanfer K. Condom breakage and slippage among men in the United States. Family Planning Perspectives. 1994;26:107-112.
  242. Grady WR, Tanfer K, Billy JOG, Lincoln-Hanson J. Men’s perceptions of their roles and responsibilities regarding sex, contraception and childrearing. Family Planning Perspectives. 1996;28(5):221–226.
  243. Grady WR, Klepinger DH, Nelson-Wally A. Contraceptive characteristics: the perceptions and priorities of men and women. Family Planning Perspectives. 1998;31(4):168–175.
  244. Grant L. Treatment of perimenopausal menorrhagia with Implanon. J Fam Plann Reprod Health Care. 2008;34(4):274.
  245. Grimes DA, Jones LB., Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006134.
  246. Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Data base Syst  Rev. 2010; (1):CD007541. doi: 10.1002/14651858.
  247. Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2013 Nov 13;11:CD007541. Retrieved from http://www.ncbi.nlm.nih.gov/.
  248. Grimes DA, Gallo MF, Halpern V et al. Fertility awareness-based methods for contraception. Cochrane Database of Systematic Reviews 2004, Issue 4. Retrieved from http://www.cochrane.org/.
  249. Grimes DA, Benson J, Singh S, Romero M et al. Unsafe abortion: the preventable pandemic. The Lancet. Sexual and Reprod Health Series.2006;368:1908- 1919.
  250. Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD001777. Retrieved from http://www.cochrane.org/
  251. Gronich N. Lavi I. Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011; 183(18):E1319-25 .
  252. Grow DR. Metabolism of endogenous and exogenous reproductive hormones. Obstet Gynecol Clin North Am 2002;29:425–436.
  253. Grunloh SD, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122(6):1214-21.
  254. Gruber D.M., Huber J.C., Melis G.B. et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 µg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 µg and desogestrel 150 mug. Treat. Endocrinol. 2006;5(2):115–121.
  255. Halpern V, Grimes DA, Lopez L, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods for contraception. Cochrane Database of Systematic Reviews. 2006 Jan 25;(1):CD004317. Retrieved from http://www.cochrane.org/.
  256. Haney AF (2008). Leiomyomata. In RS Gibbs et al., eds., Danforth’s Obstetrics and Gynecology, 10th ed., pp. 916-931. Philadelphia: Lippincott Williams and Wilkins.
  257. Hannaford PC, Iversen L, Macfarlane TV et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010; 340: 927.
  258. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007;335(7621):651.
  259. Harris WJ, Daniell J F, Baxter J W. Prior cesarean section. A risk factor for adenomyosis? J Reprod Med. 1985;30:173–175.
  260. Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive Technology, 20th edition, Ardent Media, 2011.
  261. Hatcher RA, Trussell J, Nelson AL et al. Contraceptive technology. 19th rev. ed. New York (NY): Ardent Media; 2007. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive technology 1990–1992. New York: Irving Publishers; 1988. Heikinheimo O, Gissler M, Suhonen S. Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception. 2008;78:149–154.
  262. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90(5):1583-8.
  263. Harada T, Momoeda M, Terakawa N, Taketani Y, Hoshiai H. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2011;95(6):1928-31.
  264. Heit J, Kobbervig C, James A, Petterson T, Bailey K, Melton L. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann Intern Med; 2005;143(10): 697-706.
  265. Henriet L, Kaminski M. Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. BJOG. 2001;108(1):1036-42.
  266. Hirschberg A.L., Naessen S., Stridsberg M. et al. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol. 2004;19:58-59.
  267. Hogue RCJ, Boardman LA, Stotland NL, Peipert JF. Answering questions about long-term outcomes. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA. Management of unintended and abnormal pregnancy: comprehensive abortion care. Hoboken, NJ, Wiley-Blackwell, 2009:252–263.
  268. Holt VL, Cushing-Haugen KL, Daling JR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol. 2003 Aug;102(2):252-8.
  269. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother. 2008;9(13):2317–25.
  270. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010;30:749–763.
  271. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297–3000.
  272. Jackson JE, Grobman WA, Haney E, Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gyn Obst. 2007;96(1):12-15.
  273. Jafari A, Abedi P, Sayahi M, Torkashvand R. The effect of vitamin B1 on bleeding and spotting in women using an intrauterine device: A double-blind randomised controlled trial. Eur J Contracept Reprod Health Care. 2014;19(3):180–6.
  274. Johnson JV, Lowell J, Badger GJ, etal. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomizedcontrolledtrial. ObstetGynecol 2008;111:278–284.
  275. Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000-2001. Perspect Sex Reprod Health. 2002;34(6):294-303.
  276. Jones RK, Dreweke J. Countering Conventional Wisdom: New Evidence on Religion and Contraceptive Use. New York, Guttmacher Institute, 2011. Retrieved from www.guttmacher.org/.
  277. Johnson SR, Tiplady S, Humberstone F. Survey of Usage and Awareness of Contraception Across Four European Countries. SPD Development Company Ltd. 2011. P. 133. Retrieved from http://www.es.clearblue.com/.
  278. Johnson LG, Mueller BA, Daling JR. The relationship of placenta previa and history of induced abortion. Int J Gyn Obst. 2003;81(2):191-8.
  279. Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996;55(2):94–8.
  280. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006;12(3):243–252.
  281. Induced Abortion and Mental Health: A systematic review of the evidence. National Collaborating Centre for Mental Health. December 2011. Archived from the original on 25 March 2012. Retrieved from http://www.quickiwiki.com/.
  282. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception. 1999;59(1):29–33.
  283. Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281–286.
  284. Klipping C, Duijkers I, Fortier MP et al. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care.
  285. Kloosterboer HJ, et al. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 1988;38:325-32.
  286. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4):249–256.
  287. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.
  288. Kost K, Singh S, Vaughan B et al . Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77:10–21.
  289. Kulczycki A, Kim D-J, Ann Duerr, Jamieson DJ, Macaluso M. The Acceptability of the Female and Male Condom: A Randomized Crossover Trial. Persp Sex and Repr Health. 2004; 36(3):114-119.
  290. Kulier R, Kapp N, A Metin Gülmezoglu, G Justus Hofmeyr, Linan Chen5, Aldo Campana. Medical methods for first trimester abortion. 2011. Retrieved from http://summaries.cochrane.org
  291. La FM, Ledger WL, Davidson JW, Howard DM, Jones GL. The effects of a third generation combined oral contraceptive pill on the classical singing voice. J Voice. 2007;21(6):754–61.
  292. Lahteenmaki P, Luukkainen T. Return of ovarian function after abortion. Clin Endocrinol. 1978; 8(2):123–132.
  293. Lahteenmaki P. The disappearance of HCG and return of pituitary function after abortion. Clin Endocrinol. 1978; 9(2):101–112.
  294. Lahteenmaki P. Return of ovulation after abortion and after discontinuation of oral contraceptives/ Fertility and sterility.1980; 34(3): 246.
  295. Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulm ezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects (Review). The Cochrane Library 2011, Issue 5. Electronic resource. Access mode: http://onlinelibrary.wiley.com/
  296. Lee W, Newman DR, Austin HD et al. and for the Project RESPECT Study Group. Condom Effectiveness for Reducing Transmission of Gonorrhea and Chlamydia: The Importance of Assessing Partner Infection Status. Am. J. Epidemiol. 2004;159(3):242-251.
  297. Legro RS, Pauli JG, Kunselman AR et al. Effects of Continuous Versus Cyclical Oral Contraception: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2008;93(2):420–429.
  298. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2005; 4: CD002126. Retrieved from http://summaries.cochrane.org
  299. Lete I Lasa. Inprovement of dysmenorrhoea and premenstrual syndrome in NuvaRing users – a clinical experience program in Spain. Poster in ESC, 2006.
  300. Leung VWY, Levine M, Soon JA. Mechanisms of Action of Hormonal Emergency Contraceptives. Pharmacotherapy. 2010;30(2):158–168.
  301. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013; 5: 541–556.
  302. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009 Aug 13;339:b2890. doi: 10.1136/bmj.b2890.
  303. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001-9. BMJ. 2011; 343: d6423.
  304. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosisin users of non-oral hormonal contraception: follow-up study, Denmark 2001-10, BMJ 2012;344:e2990.
  305. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66э.
  306. Lidegaard, O. Thrombotic Risks with Hormonal Contraception. Glob. libr. women’s med. 2015; DOI 10.3843/GL OWM.10388. https://www.glowm.com/
  307. Lievre M, Sitruk-Ware R. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception. 2009; 80(1):95-100
  308. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril. 1985;43(2):200–205. 
  309. Lohr PA, Fjerstad M, DeSilva U, Lyus R. Abortion. Clinical review. BMJ. 2014;348:755-762.
  310. Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. National Collaborating Centre for Women’s and Children’s Health. RCOG, 2013. Retrieved from http://www.ncbi.nlm.nih.gov/.
  311. Lopez LM, Steiner M, Grimes DA, Hilgenberg D, Schulz KF. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev. 2013 Apr 30;4:CD006964. Retrieved from http://summaries.cochrane.org.
  312. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome (Review). The Cochrane Library 2012, Issue 2. Electronic resource. Access mode: http://onlinelibrary.wiley.com/.
  313. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985;35(2):459–471.
  314. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% toal minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol.2004;50:541–53.
  315. Lucky AW, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008 Aug;82(2):143-50.
  316. Lundstrom V, Green K. Endogenous levels of prostaglandin F2 and its metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130:640-646.
  317. Mackenzie H, Draho A, Pallikadavath S, Stone W et al. What is the Impact of Contraceptive Methods and Mixes of Contraceptive Methods on Contraceptive Prevalence, Unmet Need for Family Planning, and, Unwanted and Unintended Pregnancies? An Overview of Systematic Reviews. 2011. Retrieved from http://r4d.dfid.gov.uk/.
  318. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care. 2008;13(1):17–24.
  319. Maloney JM, Dietze P, Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008;112(4):773–781.
  320. Maloney JM, Dietze P, Jr, Watson D, et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 μg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol. 2009;8(9):837–844.
  321. Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16:430–443.
  322. Mansour D, Bahamondes L, Critchley H et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83(3):202-210.
  323. Manzoli L, Vito C, Marzuillo C et al. Oral Contraceptives and Venous Thromboembolism. Drug Safety. 2012;35(3):191-205.
  324. March CM. Intrauterine adhesions. Obstet Gynecol Clin North Am. 1995;22(3):491-505.
  325. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol. 2002;100(1):65-71.
  326. Marston C, Cleland J. Relationships between Contraception and Abortion: A Review of the Evidence. Intern Family Planning Perspectives. 2003;29(1):6-13.
  327. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20 µg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet. 2011;113(2):103–7.
  328. Marrs RP. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. American journal of obstetrics and gynecology. 1979; 135(6): 731.
  329. Martinez-Astorquiza-Ortiz de Zarate T, Diaz-Martin T, Martinez-Astorquiza-Corral T. Evaluation of factors associated with noncompliance in users of combined hormonal contraceptive methods: a cross-sectional study: results from the MIA study. BMC Womens Health. 2013;13:38.
  330. Maslow AH. Motivation and Personality. New York: Harpaer & Row, 1954.
  331. McArthur JO., Tang HM, Petocz P, Samman S. Biological Variability and Impact of Oral Contraceptives on Vitamins B6, B12 and Folate Status in Women of Reproductive Age. Nutrients. 2013; 5(9): 3634–3645.
  332. McDonald-Mosley R, Burke AE. Contraceptive implants. Semin Reprod Med. 2010;28(2):110-7.
  333. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26–34.
  334. Medical eligibility criteria for contraceptive use. 4th ed. Switzerland: WHO, 2009. 169 р.
  335. Mestad R, Kenerson J, Peipert J. Reversible Contraception Update: The Importance of Long-Acting Reversible Contraception. Postgrad Medicine. 2009;121 (4):18-25.
  336. Method mix. USAID. MEASURE Evaluation Population and Reproductive Health (PRH). 2014. Retrieved from http://www.cpc.unc.edu/.
  337. Mittal S. Методы неотложной контрацепции: Комментарий БРЗ (последняя редакция: 1 ноября 2008 г.). Библиотека репродуктивного здоровья ВОЗ; Женева: Всемирная организация здравоохранения. Retrieved from http://apps.who.int/.
  338. Milsom I et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing versus an oral contraceptive containing 30 mg ethinyl estradiol and 3 mg drospirenone. Human Reproduction. 2006; 21(9): 2304–2311.
  339. Mittal S, Aggarwal P. Interventions for emergency contraception: RHL commentary (last revised: 1 November 2012). The WHO Reproductive Health Library; Geneva: World Health Organization. Retrieved from http://apps.who.int/.
  340. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–40.
  341. Moltz L, Kaiser E. Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study. Geburtshilfe Frauenheilkd. 1984;44(1):47-52.
  342. Moore J, Kennedy S and Prentice A (200З) Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). In the Cochrane Library, Oxford, Issue 1. Oxford: Update Software. Retrieved from http://summaries.cochrane.org.
  343. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 6 July 2011: CD007506. DOI: 10.1002/14651858. pub3
  344. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267–272.
  345. de Morais TL, Giribela C, Nisenbaum M. et al.  Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014;11:113-7.
  346. Moreau C, Trussell J, Rodriguez G, Bajos N, Bouyer J. Contraceptive failure rates in France: results from a population-based survey. Hum Reprod. 2007;22(9):2422-7.
  347. Moroni RM, Martins WP, Dias SV, et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest. 2015;79(3):145-52.
  348. Mueck AO, Sitruk–Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011;76:531–539.
  349. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75(5):
    865-70.
  350. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin 24 Fe). Contraception. 2007;75:16–22.
  351. Nappi RE, Albani F, Tonani S et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. Funct Neurol. 2009;24(2):71-75.
  352. Narkiewicz K, Graniero GR, D’Este D, Mattarei M, Zonzin P, Palatini P. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens. 1995;8:249–53.
  353. Niccolai L, Rowhani-Rahbar A, Jenkins H, Green S, Dunne D. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect. 2005;81(4):323–325.
  354. Novak A, de la Loge C, Abetz L. Valuation of NuvaRing acceptability in 14 countries. Presented at the 17th Word Congress of Fertility and Sterility, Melbourne, 2001.
  355. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestoge, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrin Metab. 1995;8:1816–21.
  356. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol. 2012;207(5):377.e1-8.
  357. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormon ebinding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–90.
  358. Osotimehin B, Otolorin E, Ladipo O. Sequential hormone measurements after first trimester abortion in normal Nigerian women. Advances in Contraception.1985; 1(1): 83-90.
  359. Otto C, Fuchs I, Vonk R, Fritzemeier KH. Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate. Maturitas. 2010 Apr;65(4):386-91.
  360. Palmery M, Saraceno A, Vaiarelli A, Carlomango G. Oral contraceptives and changes in nutritional requirements. Eur Rev Med Pharmacol Sci. 2013;17:1804–13.
  361. Parazzini F, Cipriani S, Chiaffarino F, Sandretti F et al. Induced abortion and risk of small-for-gestational-age birth. BJOG. 2007;114(11):1414-8.
  362. Parazzini F, Mais V, Cipriani S et al. Determinants of adenomyosis in women who underwent hysterectomy for benign gynecological conditions: results from a prospective multicentric study in Italy. Eur J Obstet Gynecol Reprod Biol. 2009 Apr;143(2):103-6.
  363. Parazzini F, Vercellini P, Panazza S/ et al. Risk factors for adenomyosis. Hum Reprod. 1997 Jun;12(6):1275-9.
  364. Parkin L, Sharples K, Hernandez R, Jick S. 2011. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139 doi:10.1136/bmj.d2139.
  365. Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing Unintended Pregnancies by Providing No-Cost Contraception. Obstet Gynecol. 2012; 120(6):1291-7.
  366. Pedersen W. Abortion and depression: A population-based longitudinal study of young women. Scandinavian Journal of Public Health. 2008;36(4):424-428.
  367. Position Statement on Women’s Mental Health in Relation to Induced Abortion. Royal College of Psychiatrists. 2008. Retrieved from http://www.rcpsych.ac.uk/.
  368. Peipert JF, Zhao Q, Allsworth JE,Petrosky E, Madden T et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105-13.
  369. Piaggio G et al. Combined estimates of effectiveness of mifepristone 10 mg in emergency contraception. Contraception. 2003; 68(6):439-46.
  370. Pingmin W, Yuepu P, Jiwen Z. Prevalence survey on condom use and infection of urogenital mycoplasmas in female sex workers in China. Contraception. 2005;72(3):217-20.
  371. Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Tha. 2005;88(2):7-10.
  372. Progestogen-only Pills. Clinical Effectiveness Unit. November 2008 (Updated 2013). RCOG: Faculty of Sexual and Reproductive Healthcare Registered in England No. 2804213 and Registered Charity No. 1019969. Retrieved from http://www.fsrh.org/.
  373. Rabe T, Luxembourg B, Ludwig M, Dinger J, Bauersachs R, Rott H, Mueck A.O., Albring C, Contraception and Thrombophilia – A statement from the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF e.V.) and the Professional Association of German Gynaecologists (BVF e.V.) J Reproduktionsmed Endokrinol 2011;8(1) 178–218.
  374. Rafie S, Borgelt L, Koepf ER et al. Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest. Int J Womens Health. 2013; 5: 313 –321.
  375. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 2008;53(9):729–741.
  376. Raps M, Helmerhost F, Fleisher K et al. Sexhormone-binding globulinas a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012;10(6):992-997. 
  377. Raymond E, Taylor D, Trussell J, Steiner MJ. Minimum effectiveness of the levonorgestrel regimen of emergency contraception. Contraception. 2004;69(1):79-81.
  378. Raymond EG, Goldberg A, Trussell J, Hays M, Roach E, Taylor D. Bleeding patterns after use of levonorgestrel emergency contraceptive pills. Contraception. 2006;73(4):376-81.
  379. Real Choices: Women, Contraception and Unplanned Pregnancy. Marie Stopes International, 2008. 15 р.
  380. Reyniak JV, Gordon M, Stone ML, Sedlis A. Endometrial regeneration after voluntary abortion. Obstet Gynecol. 1975;45(2):203-10.
  381. Rogers EM. Diffusion of Innovations. 4-th Edition. Simon and Schuster, 2010. — 518 p.
  382. Rose SB, Lawton BA, Brown SA. Uptake and adherence to long-acting reversible contraception post-abortion. Contraception. 2010;82(4):345-53
  383. Rosenberg MJ. Burnhill MS. Waugh MS. Grimes DA. Hillard PJA. Compliance and oral contraceptives: A review. Contraception. 1995;52:137–141.
  384. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 1999;180(Pt 2):276–9.
  385. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293(6543):359–62.
  386. Royal College of General Practitioners’ Oral Contraception Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet. 1977;1:624.
  387. Royal College of General Practitioners: Oral contraceptives, venous thrombosis and varicose veins // J.R.Coll.Gen.Pract. 1978; 28: 393-399.
  388. Royal College of Obstetricians and Gynaecologists (RCOG). The care of women requesting induced abortion. London (England): 2011 Nov. 130 p. (Evidence-based Clinical Guideline; no. 7). Retrieved from http://www.rcog.org.uk.
  389. Royal College of Obstetricians and Gynaecologists (RCOG). Contraceptive Choices for Women with Cardiac Disease. FACULTY OF SEXUAL &REPRODUCTIVE HEALTHCARE. 2014. Retrieved from http://www.fsrh.org.
  390. Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis. Guideline no. 24, October 2006. Retrieved from http://www.endometriozisdernegi.com/.
  391. Royal College of Obstetricians and Gynaecologists. Induced termination of pregnancy and future reproductive outcomes – current evidence. 16 September 2009. Retrieved from http://www.rcog.org.uk/.
  392. Royal College of Obstetrics and Gynaecologists (RCOG) and the British Society for Gynaecological Endoscopy (BSGE). Management of Endometrial Hyperplasia. Green-top Guideline No.67. RCOG/BSGE Joint Guideline, February2016.
  393. Roumen FJME, Apter D, Mulders TMT et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469–75.
  394. Rowan SP, Someshwar J, Murray P. Contraception for primary care provider. Adolescent medicine: state of the art reviews. 2012;23(1):95–110.
  395. Russo JA., Achilles S., DePineres T., Gil L. Controversies in family planning: postabortal pelvic inflammatory disease. Contraception. 2012; 87(4): 497-503.
  396. Rowan SP, Someshwar J, Murray P. Contraception for primary care providers. Adolescent medicine: state of the art reviews. 2012; 23 (1): 95–110.
  397. Saav I, Stephansson O, Gemzell-Danielsson K. Early versus Delayed Insertion of Intrauterine Contraception after Medical Abortion — A Randomized Controlled Trial. 2012. ClinicalTrials.gov NCT01537562
  398. Sachdeva S. HIRSUTISM: EVALUATION AND TREATMENT. Indian J Dermatol. 2010;55(1): 3–7.
  399. Safe abortion: technical and policy guidance for health systems. Second edition. World Health Organization, 2012: 134 p.
  400. Sahin Y, Bayram F, Kelestimur F, Muderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest. 1998 Jun;21(6):348-52.
  401. Sandset PM, Hoibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009;123(2):70–73. 
  402. Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod. 2003;18(3):522-6.
  403. Schindler AE, Henkel A, Moore C, Oettel M. Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. Arch Gynecol Obstet. 2010;282(5):507-14.
  404. Schindler AE, Mangold K, Friedrich E, Keller E, Göser R. Therapy of androgenetic symptomatology with cyproterone acetate and ethinyl estradiol. Arch Gyn Obst. 1978;225(2):103–7.
  405. Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. 2012;38(2):84-93.
  406. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 1995;85(5 Pt 1):793–801.
  407. Schramm GA, Schrah G. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception. 2011;84(4):390-401. Epub 2011 May 26.
  408. Schreiber CA, Sober S, Ratcliffe S, Creinin M. Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception. 2011; 84: 230–233.
  409. Shah PS, Zao J. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analysis. BJOG. 2009;116:1425-1442.
  410. Secura GM, Madden T, McNicholas C et al. Provision of No-Cost, Long-Acting Contraception and Teenage Pregnancy. N Engl J Med. 2014;371:1316-1323.
  411. Selected practice recommendations for contraceptive use – 2nd ed., World Health Organization, 2005; 166 р. Retrieved from http://www.euro.who.int/
  412. Senikas V, Dunn S, Guilbert E, Black A. Missed Hormonal Contraceptives: New Recommendations Committee Opinion. Clinical Practice Guidelines. SOGC, 2008. Retrieved from http://sogc.org/.
  413. Serup J, Bostofte E, Larsen S et al. Natural oestrogens for oral contraception // Lancet. 1979;2: 471–472.
  414. Severi F.M., Bocchi C., Luisi S. et al. Ultrasound and diagnosis of abnormal uterine bleeding. Gynecol. Endocrinol. (Abstr.). 2004. P.156.
  415. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005; 152 (3):466–473/
  416. Singh S, Wulf D, Hussain R, Bankole A, Sedgh G. Abortion Worldwide: A Decade of Uneven Progress (Report). New York: Guttmacher Institute. 2009. 65 р. Retrieved from http://www.guttmacher.org/.
  417. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007;357(16):1620–1630.
  418. Shimoni N, Davis A, Ramos M, Rosario L, Westhoff C. Timing of Copper Intrauterine Device Insertion After Medical Abortion: A Randomized Controlled Trial. Obst Gyn. 2011;118(3):623–628.
  419. Schindler AE, Mangold K, Friedrich E et al. Therapy of androgenetic sympatomatology with cyproterone acetate and ethinyl estradiol. Arch Gynakol. 1978;225(2):103-7.
  420. Shrestha A. Risk factors for adenomyosis. J Nepal Health Res Counc. 2012 Sep;10(22):229-33.
  421. Sidneya S, Cheethamb T, Frederick A et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2012;87:93–100.
  422. Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013;87:93-100.
  423. Singh S, Darroch JE, Vlassoff M, Nadeau J. Adding it Up: The Benefits of Investing In Sexual and Reproductive Health Care (Report). New York: The Guttmacher Institute and UNFPA. 2009. 41 р. Retrieved from http://www.guttmacher.org/.
  424. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology. 2000;11(2):
    106–10.
  425. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61 (1-2):151-157.
  426. Sonnenberg FA, Burkman RT, Hagerty CG, Speroff L, Speroff T. Costs and net health effects of contraceptive methods. Contraception. 2004;69:447–59.
  427. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol. 1990;43(11):1221–30.
  428. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52(5):587–594.
  429. Starczewski A, Iwanicki M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol. 2000;71(9):1221-5.
  430. Stegeman BH, Helmerhorst F, Vos HL, Rosendaal FR, van Hylckama Vlieg A. Sex hormone-binding globulin levels are not causally related wuth venous thrombosis risk inwomen not using hormonal contraceptives. J Thromb Haemost 2012; 10: 2061–7.
  431. Stoddard A; McNicholas C; Peipert JF. Efficacy and Safety of Long-Acting Reversible Contraception. Drugs. 2011;71(8):969–980.
  432. Stotland NL. Abortion and psychiatric practice. J Psychiatr Pract. 2003;9(2):139–149.
  433. Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010;93(6):2035-41.
  434. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641.
  435. Sugiura K, Kobayashi T, Ojima T. Thromboembolism as the adverse event of combined oral contraceptives in Japan. Thrombosis Research. 2015;136(6):1110–1115.
  436. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception. 2004;70(4):281-7.
  437. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186(6):1142-9.
  438. Sullivan TM, Bertrand JT, Rice J, Shelton JD. Skewed contraceptive method mix: why it happens, why it matters. Journal of Biosocial Science. 2006; 38(4):501-521.
  439. Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. Contraception. 2004;69:23–26.
  440. Swingle HM, Colaizy TT, Zimmerman MB, Morriss FH. Abortion and the risk of subsequent preterm birth: A systematic review with meta-analyses. J Rrepro Med. 2009;54:95-108.
  441. Szymusik I, Szpotanska-Sikorska M, Mazanowska N. Contraception in Women After Organ Transplantation. Transplantation Proceedings. 2014;46:3268-3272.
  442. Taran F A, Weaver A L, Coddington C C. et al. Characteristics indicating adenomyosis coexisting with leiomyomas: a case-control study. Hum Reprod. 2010(а);25:1177–1182.
  443. Taran F A, Wallwiener M, Kabashi D. et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012;285:1571–1576.
  444. Taran F.A., Stewart E.A., Brucker S. Adenomyosis: Epidemiology, Risk Factors, Clinical Phenotype and Surgical and Interventional Alternatives to Hysterectomy. Geburtshilfe Frauenheilkd. 2013 Sep; 73(9): 924–931.
  445. Taran FA, Weaver A L, Coddington C C. et al. Understanding adenomyosis: a case control study. Fertil Steril. 2010(б);94:1223–1228.
  446. Templeman C, Marshall S F, Ursin G. et al. Adenomyosis and endometriosis in the California Teachers Study. Fertil Steril. 2008;90: 415–424.
  447. Taylor VM, Kramer MD, Vaughan TL, Peacock S. Placental previa in relation to induced and spontaneous abortion: a population-based study. Obstet Gynecol. 1993;82(1):88-91.
  448. Templeton A., Grimes D.A. A Request for Abortion. N Engl J Med. 2011;365:2198-204.
  449. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316(11):650–5.
  450. Thompson MM. Women’s attitudes, perceptions, and knowledge about the vagina. Sexuality, Reproduction and Menopause. 2006;4:74–79.
  451. Thompson KM, Speidel JJ, Saporta V, Waxman NJ, Harper CC. Contraceptive policies affect post-abortion provision of long-acting reversible contraception. Contraception. 2011;83(1):41-7.
  452. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–42.
  453. Trussell J, Rodriguez G, Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraceptio». Contraception. 1999;59 (3):147–51.
  454. Trussell J, Ellertson C, von Hertzen H, Bigrigg A, Webb A, Evans M, Ferden S, Leadbetter C. Estimating the effectiveness of emergency contraceptive pills. Contraception. 2003;67(4):259–65.
  455. Trussel J. Contraceptive efficacy. In: Hatcher RA, Trussel J, Stewart F, Nelson A, Gates W, Guest F, Kowal D. Contraceptive Technology. Eighteenth Revised Edition. New York, NY, Ardent Media, 2007; p. 747–826.
  456. Trussell J. Contraceptive failure in the United States. Contraception. 2011;84:397-404.
  457. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008 May;77(5):337-43.
  458. Zhang L, Chen J, Wang Y, Ren F, Yu W, Cheng L. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod 2009;24(7):1605-1.
  459. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelialNOsynthase via glucocorticoid receptors. FASEB J. 2007;21: 265–273.
  460. Zerr-Fouineau M, Jourdain M, Boesch C et al. Certain progestins prevent the enhancing effect of 17β-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cell. Arterioscler. Thromb. Vasc. Biol. 2009;29:586–593.
  461. van den Heuvel MW, van Bragt AJM, Alnabawy AKM et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–74.
  462. van der Spuy ZM, Le Roux PA, Matjila MJ. Cyproterone acetate appears to be as effective as other medications for hirsutism in women caused by excessive androgen production by the ovaries.  2003, Issue 4. Art. No.: CD001125. http://www.ncbi.nlm.nih.gov/
  463. van Vloten WA, van Haselen CW, van Zuuren EJ et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4):2-15.
  464. van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103(4):241-51.
  465. van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015 Apr 28;(4):CD010334. doi: 10.1002/14651858.CD010334.pub2.
  466. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) – A systematic enquiry and overview. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2006;125:9–28.
  467. Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics. 2004;22:1141–51.
  468. Vercellini P, Eskenazi B, Consonni D et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-70.
  469. Vlieg AVH, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
  470. Virk MS, Zhang J, Olsen J. Abortion and the Risk of Subsequent Adverse Pregnancy Outcomes. New England Journal of Medicine. 2007;357(7):648–653.
  471. Voigt M, Henrich W, Zygmunt M, Friese K et al. Is induced abortion a risk factor in subsequent pregnancy. Journal of Perinatal Medicine 2009;37(2):144-9.
  472. Vrbikova J., Cibula D. Combined oral contraceptives in the treatment of PCOS. Hum. Reprod. Update. 2005;11(3):277-291.
  473. Walch K et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis — a pilot study. Contraception. 2009;79:29–34.
  474. Wang C, Di W, Liao Q, et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(5):355-9.
  475. Webb JL. Nutritional effects of oral contraceptive use: a review. J Reprod Med. 1980;25(4):150-6.
  476. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255. Retrieved from http://onlinelibrary.wiley.com/.
  477. Wenger NS, Kusseling FS, Shapiro MF. Misunderstanding of ‘safer sex’ by heterosexually active adults. Public Health Rep. 1995;110(5):618–621.
  478. Weiss G, Maseelall P, Schott L L. et al. Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women*s Health Across the Nation (SWAN) Fertil Steril. 2009;91:201–206.
  479. Westendorp, IC, Ankum, WM, Mol, BW, and Vonk, J. Prevalence of Asherman’s syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Hum Reprod 1998;13(12):3347-50.
  480. Westhoff C, Kaunitz AM, Korver T et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial. Obstet Gynecol. 2012;119:989–999.
  481. WHO. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997;349:1202-1209.
  482. WHO. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international multicentre case-control study. Contraception. 1998;57:315-324.
  483. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med. 2000;45(3):241–7.
  484. Willis SA, Kuehl TJ, Spikerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74(2):100–103.
  485. Winer RL, Hughes JP, Feng Q, O’Reilly S et al. Condom Use and the Risk of Genital Human Papillomavirus. Infection in Young Women. N Engl J Med. 2006;354:2645-54.
  486. Winikoff B. Is One of These Things Not Just Like the Other? Why Abortion Can’t Be Separated from Contraception. LISBON 2014: An International Summit on Reproductive Choice. 2014:8-12.
  487. WHO. Model list of essential medicines. 19th ed. Geneva: WHO, 2015. http://mednet3.who.int/EMLib/
  488. World Abortion Policies. United Nations, Department of Economic and Social Affairs, Population Division 2012. Retrieved from http://www.un.org/.
  489. World Contraceptive Use-2007. Wall Chart. UN Department of Economic and Social Affairs, Population Division.
  490. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea (Review). The Cochrane Library 2009, Issue 4. Electronic resource. Access mode: http://onlinelibrary.wiley.com/.
  491. Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):794-802.
  492. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008 May;77(5):337-43.

Предлагаем вашему вниманию журналы, издающиеся в издательстве «Академия Естествознания»
(Высокий импакт-фактор РИНЦ, тематика журналов охватывает все научные направления)

«Современные проблемы науки и образования» список ВАК ИФ РИНЦ = 1,006
«Фундаментальные исследования» список ВАК ИФ РИНЦ = 1,674
«Современные наукоемкие технологии» список ВАК ИФ РИНЦ = 0,940
«Успехи современного естествознания» список ВАК ИФ РИНЦ = 0,775
«Международный журнал прикладных и фундаментальных исследований» ИФ РИНЦ = 0,593
«Международный журнал экспериментального образования» ИФ РИНЦ = 0,425
«Научное Обозрение. Биологические Науки» ИФ РИНЦ = 0,400
«Научное Обозрение. Медицинские Науки» ИФ РИНЦ = 0,801
«Научное Обозрение. Экономические Науки» ИФ РИНЦ = 0,871
«Научное Обозрение. Педагогические Науки» ИФ РИНЦ = 0,733
«Научное Обозрение. Технические Науки» ИФ РИНЦ = 0,695
«European journal of natural history» ИФ РИНЦ = 0,301
«Международный студенческий научный вестник»
Издание научной и учебно-методической литературы ISBN РИНЦ DOI
РЕЦЕНЗИИ и ОТЗЫВЫ
кандидатов и докторов наук
на статьи, авторефераты, диссертации, монографии, учебники, учебные пособия
Академия Естествознания готовит к изданию реестр новых научных направлений, разработанных российскими учеными